Is there a relationship between dietary MSG and [corrected] obesity in animals or humans?

John T Brosnan1, Adam Drewnowski, Mark I Friedman

  • 1Department of Biochemistry, Memorial University of Newfoundland, St. John's, NL, A1B 3X9, Canada, jbrosnan@mun.ca.

Amino Acids
|June 15, 2014
PubMed

Insights

Monosodium glutamate (MSG) is safe and does not cause weight gain or affect fat metabolism. Dietary MSG does not reach the brain because it is metabolized in the gut.

Area of Science:

  • Food Science
  • Nutritional Science
  • Metabolic Research

Background:

  • Monosodium glutamate (MSG) is a widely used food flavoring agent known for its savory taste.
  • Past research established MSG safety and minimal physiological effects, primarily on taste.
  • Recent studies suggest a link between MSG consumption and obesity/fat metabolism issues, often attributed to brain effects.

Purpose of the Study:

  • To address conflicting findings on MSG's impact on weight and fat metabolism.
  • To evaluate the scientific basis for claims linking dietary MSG to adverse health outcomes.
  • To clarify the physiological fate of ingested MSG and its potential systemic effects.

Main Methods:

  • A symposium reviewed existing epidemiologic, animal, and human intervention studies.
  • Analysis focused on the metabolic pathways and bioavailability of ingested glutamate.
  • Comparison of oral MSG ingestion versus direct injection studies in rodents was conducted.

Main Results:

  • The proposed link between MSG intake and weight gain is likely due to confounding environmental factors associated with the "nutrition transition."
  • Controlled dietary studies in animals and humans show no significant effect of MSG on body weight.
  • Rodent studies involving MSG injection into the brain are not applicable to dietary MSG ingestion due to glutamate's metabolic compartmentalization.

Conclusions:

  • Dietary MSG does not significantly cross biological barriers like the gut, placenta, or blood-brain barrier.
  • Ingested glutamate is largely metabolized in the gut, preventing systemic access to the brain.
  • Normal dietary intake of MSG is unlikely to influence energy intake, body weight, or fat metabolism.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.8K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324